Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Interest Expenses (2020 - 2024)

Historic Interest Expenses for Seres Therapeutics (MCRB) over the last 5 years, with Q1 2024 value amounting to $618000.0.

  • Seres Therapeutics' Interest Expenses fell 6827.52% to $618000.0 in Q1 2024 from the same period last year, while for Dec 2024 it was $618000.0, marking a year-over-year decrease of 8796.49%. This contributed to the annual value of $2.5 million for FY2023, which is 5900.33% down from last year.
  • Latest data reveals that Seres Therapeutics reported Interest Expenses of $618000.0 as of Q1 2024, which was down 6827.52% from $3.2 million recorded in Q2 2023.
  • In the past 5 years, Seres Therapeutics' Interest Expenses registered a high of $3.2 million during Q2 2023, and its lowest value of $618000.0 during Q1 2024.
  • For the 5-year period, Seres Therapeutics' Interest Expenses averaged around $1.2 million, with its median value being $744000.0 (2021).
  • As far as peak fluctuations go, Seres Therapeutics' Interest Expenses skyrocketed by 15474.25% in 2022, and later plummeted by 6827.52% in 2024.
  • Seres Therapeutics' Interest Expenses (Quarter) stood at $759000.0 in 2020, then fell by 2.77% to $738000.0 in 2021, then surged by 154.74% to $1.9 million in 2022, then skyrocketed by 69.52% to $3.2 million in 2023, then crashed by 80.61% to $618000.0 in 2024.
  • Its last three reported values are $618000.0 in Q1 2024, $3.2 million for Q2 2023, and $1.9 million during Q1 2023.